Stock screener

SRRK

Conviction 100HealthcareScan · Thu, Jun 25, 2026
SRRK$53.84+2.88%
ResistanceSupportVol 14Insider sell
63 bars
4
Vol MA14 1.69M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Scholar Rock Holding CorpBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.scholarrock.com
Price53.84
Change+2.88%
Gap-0.01%
Rel volume3.06×
Avg volume1.54M
Avg $ vol74.36M
SMA 2047.01
SMA 5047.68
SMA 20042.50
Price vs 50+12.90%
Price vs 200+26.66%
MA stackbullish
50/200 cross
Supertrendup · 46.18
RSI (14)70
MACD hist0.98
MACD crossbull · 5d
Stoch %K / %D100 / 94
ADX (14)22
+DI / −DI35 / 12
RSI divergence
MACD divergence
ATR %+4.12%
ADR %4.40%
52w high53.84
52w low27.92
From 52w high+0.00%
Above 52w low+92.82%
New 52w highYes
SqueezeOff
Bollinger width24.80%
%B1.09
Donchian pos99.95%
Donchian high53.84
Donchian low43.23
AVWAP (52w high)53.20
vs AVWAP high+1.20%
AVWAP (52w low)44.99
vs AVWAP low+19.66%
OBV trendUp
Chaikin MF (20)0.11
Today vs 20d3.06×
Avg vol (14d)1.69M
Avg vol (20d)1.54M
Avg $ vol (20d)74.36M
Market cap6.45B
RS 3m (vs SPY)+11.45%
RS 6m (vs SPY)+11.47%
RS line new highNo
Trend template8/8
Technical rank85.0
1 week+14.66%
1 month+4.51%
3 months+18.50%
6 months+19.10%
1 year+61.13%
YTD+25.78%
P/E-17.07
P/B23.37
P/S
P/FCF-21.46
EPS-3.29
Div yield
ROE-136.93%
ROA-70.61%
Debt/Eq0.71
Current8.64
EV/EBITDA-16.23
Gross margin
Net margin
Rev growth-100.00%
EPS growth-53.45%
Price target59.40
Target upside10.34%
Analyst ratingBuy
Institutional117.99%
Ent. value6.22B
Revenue0
Net income-105.51M
Gross profit
Free cash flow-300.64M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out119.83M
Employees289
ListedThu, May 24, 2018
Free float78.82M
Float %77.3%
Short interest16.43M
Days to cover13.6d
Short volume33.0%
Squeeze score80 / 100
Next earningsWed, Aug 5, 2026 (41d)
EPS forecast−$0.84 · 6 est
Last EPS vs est−$0.83 vs −$0.82
Last surprise-1.2% miss
Setup gradeA+
Conviction100 / 100
Pattern quality
Tech rank85.0 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance51.79
Support43.26
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in SRRK

All disclosures →
No recent disclosed trades by Congress in SRRK. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in SRRK · 9 buys

InsiderSideShares
Reed Joshua
Director · Common Stock · 2026-06-04
Grant6.84K
Burow Kristina
Director · Stock Option (Right to Buy) · 2026-06-04
Grant4.31K
Peng Katie
Director · Stock Option (Right to Buy) · 2026-06-04
Grant4.31K
AKKARAJU SRINIVAS
Director · Common Stock · 2026-06-04
Other
AKKARAJU SRINIVAS
Director · Common Stock · 2026-06-04
Grant6.84K
Burow Kristina
Director · Common Stock · 2026-06-04
Grant6.84K
AKKARAJU SRINIVAS
Director · Stock Option (Right to Buy) · 2026-06-04
Grant4.31K
FLIER JEFFREY S.
Director · Stock Option (Right to Buy) · 2026-06-04
Grant4.31K
Peng Katie
Director · Common Stock · 2026-06-04
Grant6.84K
Gilman Michael
Director · Stock Option (Right to Buy) · 2026-06-04
Grant4.31K

SEC filings

EDGAR filings in SRRK · 1 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.